AbbVie links up with London VC firm to map out new anti-inflammatory companies

While AbbVie has mainly been garnering headlines for its cancer and neurological pipelines in recent months, the Big Pharma clearly still has an eye on the inflammatory market. Its latest move is a team-up with London-based venture fund Deep Science Ventures to create one or more companies targeting this therapy area.